Stock Taper
INAB
IN8BIO, INC.
NASDAQ
$1.20
▲ UP 3.45% (0.04)

KEY STATISTICS

Market Cap$11.51 M
52w High$2.73
52w Low$0.88
Dividend Yield
Frequency
P/E-0.74
Volume22.39K
Shares Out.9.59M

COMPANY

LEADERSHIP

William T.
CHIEF EXECUTIVE
William T.

COMPENSATION 2026

Salary$397,800
Stock Awards$0
Incentive Plan Pay$336,600
All Other Comp.$9,000
Total$953,720

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 30, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
18

PRICE TARGET

Target High$4.00
Target Low$4.00
Target Median$4.00
Target Consensus$4.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2025-06-06Reverse1:30

PRICE

$1.20 ▲ UP 3.45% (+$0.04)
OVERLAYS
$1.16$1.18$1.20$1.229:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.20

About IN8bio, Inc.

https://in8bio.com ↗

IN8bio, Inc. is a clinical-stage biotech developing gamma-delta T cell therapies for cancers, with lead candidates INB-200 and INB-100 in Phase I trials for glioblastoma, solid tumors, and leukemia.

INDUSTRY

Biotechnology

A PRODUCT IN8BIO, INC. IS KNOWN FOR

INB-100
INB-100

IN8bio is developing INB-100, a gamma-delta T cell therapy for high-risk AML patients undergoing stem cell transplantation, with a focus on advancing this lead candidate as of late 2024.

COMPETITORS

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

DIRECTOR
FAIRBAIRN EMILY
Sale · 724.6K shares
2026-05-27
DIRECTOR
Graff Jeremy R.
Purchase · 22.0K shares
2026-05-09
DIRECTOR
Brandt Peter C.
Purchase · 22.0K shares
2026-05-09
DIRECTOR, OFFICER: CEO
Ho William Tai-Wei
Purchase · 154.5K shares
2026-05-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
BCDA$1.08COMPARE
PHIO$1.08COMPARE
KPRX$2.55COMPARE
APRE$0.79COMPARE
ACXP$1.42COMPARE
RNAZ$2.06COMPARE
APVO$1.74COMPARE
HCWB$2.94COMPARE